That wont necessarily translate into steep revenue drops in 2026 though
They are not advised for people with a personal or family history of MTC or MEN2
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
The right foods can help you stay full longer, support healthy digestion, and make it easier to manage blood sugar levels
It is important to treat any retatrutide available outside of a legitimate clinical trial with serious caution
Users typically report noticeable libido improvements within 3-5 days, with peak effects achieved by week 2-3